Here’s Who Just Picked Up Taiwan Fund Inc (NYSE:TWN) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Taiwan Fund Inc (NYSE:TWN) reported that Lazard Asset Management Llc. has picked up 1,729,646 of common stock as of 2017-03-20.
The acquisition brings the aggregate amount owned by Lazard Asset Management Llc. to a total of 1,729,646 representing a 21.03% stake in the company.
For those not familiar with the company, The Taiwan Fund, Inc. is a diversified, closed-end management investment company. The Fund’s investment objective is to seek long-term capital appreciation through investment primarily in equity securities listed on the Taiwan Stock Exchange (TSE) in the Republic of China (ROC). The Fund invests in various sectors, including biotechnology and medical care; building material and construction; cement; chemical; communications and Internet; computer and peripheral equipment; electric and machinery; electronic parts and components; financial and insurance; foods; oil, gas and electricity; optoelectronic; plastics; semiconductor; shipping and transportation; textiles, and trading and consumers’ goods. The Fund’s investment advisor is JF International Management Inc.
A glance at Taiwan Fund Inc (NYSE:TWN)’s key stats reveals a current market capitalization of 320.5 Million based on 8.22 Million shares outstanding and a price at last close of $17.78 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2010-09-29, Skinner picked up 4,900 at a purchase price of $16.50. This brings their total holding to 4,900 as of the date of the filing.
On the sell side, the most recent transaction saw Skinner unload 4,900 shares at a sale price of $17.09. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Taiwan Fund Inc (NYSE:TWN) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Celgene Corp /de/ Picked Up Alliqua Biomedical Inc. (NASDAQ:ALQA) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Alliqua Biomedical Inc. (NASDAQ:ALQA) reported that Celgene Corp /de/ has picked up 8,025,194 of common stock as of 2017-03-16.
The acquisition brings the aggregate amount owned by Celgene Corp /de/ to a total of 8,025,194 representing a 19.9% stake in the company.
For those not familiar with the company, Alliqua BioMedical, Inc. is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc. The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. The Company’s commercial wound care portfolio consists of over four product categories, such as Human Biologics; Antimicrobial Protection; Exudate Management and Contract Manufacturing. Human Biologics include BIOVANCE and Extracellular Matrix (ECM). Under Antimicrobial Protection, the Company offers TheraBond 3D Antimicrobial Barrier Systems and SilverSeal.
A glance at Alliqua Biomedical Inc. (NASDAQ:ALQA)’s key stats reveals a current market capitalization of 17.77 Million based on 35.11 Million shares outstanding and a price at last close of $0.599 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-02-27, Celgene picked up 4,000,000 at a purchase price of $0.50. This brings their total holding to 7,046,100 as of the date of the filing.
On the sell side, the most recent transaction saw Kalen unload 24,057,980 shares at a sale price of $0.04. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Alliqua Biomedical Inc. (NASDAQ:ALQA) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Guess Who Picked Valeant Pharmaceuticals International Inc. (NYSE:VRX) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Valeant Pharmaceuticals International Inc. (NYSE:VRX) reported that Va Partners I, Llc. has picked up 16,937,431 of common stock as of 2017-03-16.
The acquisition brings the aggregate amount owned by Va Partners I, Llc. to a total of 16,937,431 representing a 4.9% stake in the company.
For those not familiar with the company, Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.
A glance at Valeant Pharmaceuticals International Inc. (NYSE:VRX)’s key stats reveals a current market capitalization of 3.87 Billion based on 341.19 Million shares outstanding and a price at last close of $11.20 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-03-15, De picked up 10,000 at a purchase price of $10.80. This brings their total holding to 25,190 as of the date of the filing.
On the sell side, the most recent transaction saw Pershing unload 18,114,432 shares at a sale price of $11.00. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Valeant Pharmaceuticals International Inc. (NYSE:VRX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Rti Surgical Inc. (NASDAQ:RTIX) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Rti Surgical Inc. (NASDAQ:RTIX) reported that Krensavage Asset Management, Llc. has picked up 3,561,351 of common stock as of 2017-03-16.
The acquisition brings the aggregate amount owned by Krensavage Asset Management, Llc. to a total of 3,561,351 representing a 6.1% stake in the company.
For those not familiar with the company, RTI Surgical, Inc. is engaged in producing orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. The Company uses natural tissues, metals and synthetics process to produce its products. The Company’s business primarily consists of six categories, such as spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), dental and surgical specialties. It processes donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine and porcine animal tissue in producing allograft and xenograft implants utilizing BIOCLEANSE, TUTOPLAST and CANCELLE SP sterilization processes, and manufactures metal and synthetic implants for distribution to hospitals and surgeons. The Company distributes its implants and services in approximately 50 states and in over 45 countries across the world.
A glance at Rti Surgical Inc. (NASDAQ:RTIX)’s key stats reveals a current market capitalization of 219.23 Million based on 58.46 Million shares outstanding and a price at last close of $3.75 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-03-02, Singer picked up 10,000 at a purchase price of $3.79. This brings their total holding to 30,270 as of the date of the filing.
On the sell side, the most recent transaction saw Smith unload 15,000 shares at a sale price of $4.31. This brings their total holding to 18,225.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Rti Surgical Inc. (NASDAQ:RTIX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Adage Capital Management is Buying Fluidigm Corp (NASDAQ:FLDM) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Fluidigm Corp (NASDAQ:FLDM) reported that Adage Capital Management has picked up 1,546,209 of common stock as of 2017-03-13.
The acquisition brings the aggregate amount owned by Adage Capital Management to a total of 1,546,209 representing a 5.29% stake in the company.
For those not familiar with the company, Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.
A glance at Fluidigm Corp (NASDAQ:FLDM)’s key stats reveals a current market capitalization of 146.92 Million based on 29.21 Million shares outstanding and a price at last close of $4.92 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-02-15, Levin picked up 825 at a purchase price of $6.00. This brings their total holding to 6,344,568 as of the date of the filing.
On the sell side, the most recent transaction saw Worthington unload 6,000 shares at a sale price of $11.50. This brings their total holding to 6,815.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Fluidigm Corp (NASDAQ:FLDM) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
D E Shaw is Buying Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) reported that D E Shaw has picked up 3,707,857 of common stock as of 2017-03-06.
The acquisition brings the aggregate amount owned by D E Shaw to a total of 3,707,857 representing a 5.0% stake in the company.
For those not familiar with the company, BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its drug candidates include RAPIVAB, RAPIACTA, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, BCX4430 and Forodesine. Its product RAPIVAB contains peramivir. Peramivir is an intravenous neuraminidase inhibitor approved in various countries for the treatment of patients with influenza, in the United States as RAPIVAB. RAPIVAB is used for the treatment of acute uncomplicated influenza. Its BCX4430 is a broad-spectrum antiviral (BSAV) research program.
A glance at Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX)’s key stats reveals a current market capitalization of 597.06 Million based on 73.96 Million shares outstanding and a price at last close of $7.80 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-02-05, Baker picked up 45,000 at a purchase price of $6.33. This brings their total holding to 12,894,240 as of the date of the filing.
On the sell side, the most recent transaction saw Staab unload 3,250 shares at a sale price of $7.45. This brings their total holding to 124,187.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Guess Who Picked Corbus Pharmaceuticals (NASDAQ:CRBP) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) reported that Stern Adam K has picked up 2,427,250 of common stock as of 2017-03-02.
The acquisition brings the aggregate amount owned by Stern Adam K to a total of 2,427,250 representing a 4.9% stake in the company.
For those not familiar with the company, Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases. Its product, Resunab, is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Resunab is being evaluated in approximately three separate Phase II studies for the treatment of cystic fibrosis, systemic sclerosis and skin-predominant dermatomyositis. The United States Food and Drug Administration has granted Resunab Orphan Drug Designation, as well as Fast Track Status, for both cystic fibrosis and systemic sclerosis. Resunab is in Phase II clinical stage for the treatment of Systemic Lupus Erythematosus.
A glance at Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP)’s key stats reveals a current market capitalization of 461.19 Million based on 44.44 Million shares outstanding and a price at last close of $9.76 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-11-22, Cohen picked up 1,340 at a purchase price of $7.64. This brings their total holding to 4,204,562 as of the date of the filing.
On the sell side, the most recent transaction saw Burstein unload 200,000 shares at a sale price of $3.04. This brings their total holding to 3,594,846.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Guess Who Picked Up Polarityte Inc. (NASDAQ:COOL) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Polarityte Inc. (NASDAQ:COOL) reported that Honig Barry C has picked up 465,738 of common stock as of 2017-03-02.
The acquisition brings the aggregate amount owned by Honig Barry C to a total of 465,738 representing a 10.73% stake in the company.
For those not familiar with the company, PolarityTE, Inc., formerly Majesco Entertainment Company, is the owner of patent applications and know-how related to regenerative medicine and tissue engineering, as well as software applications used in diagnosis and treatment related to regenerative medicine. The Company seeks to develop and obtain regulatory approval for technology that will utilize a patient’s own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. The Company’s PolarityTE platform simplifies regeneration and allows cells to function naturally. The platform can be applied across all cells, tissues and composite structures. The Company focuses on various products, including SkinTE, OsteoTE, AngioTE, MyoTE, CartTE, AdiposeTE and NeuralTE. The Company, through SkinTE, is focused on supplying an autologous construct to regenerate a patient’s skin due to a variety of injuries and conditions.
A glance at Polarityte Inc. (NASDAQ:COOL)’s key stats reveals a current market capitalization of 26.89 million based on 4.25 Million shares outstanding and a price at last close of $6.17 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-02-24, Elliott picked up 2,500 at a purchase price of $7.71. This brings their total holding to 324,648 as of the date of the filing.
On the sell side, the most recent transaction saw Aronson unload 2,500 shares at a sale price of $1.21. This brings their total holding to 60,919.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Polarityte Inc. (NASDAQ:COOL) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.